{{Rsnum
|rsid=4238001
|Gene=SCARB1
|Chromosome=12
|position=124863717
|Orientation=plus
|GMAF=0.0753
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=SCARB1
}}{{PharmGKB
|RSID=rs4238001
|Name_s=SCARB1: G2S
|Gene_s=SCARB1
|Feature=
|Evidence=PubMed ID:18542840
|Annotation=This variant was significantly associated with postfenofibrate change for triglycerides. Subjects bearing minor allele A tend to have higher responsiveness to fenofibrate in lowering TG. A total of 1,327 subjects (639 men and 688 women) from 148 families were genotyped. Of these 1,327 subjects, 861 subjects (427 men and 434 women) went through the fenofibrate trial and had complete lipid phenotype and genotype data.
|Drugs=fenofibrate
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA162167943
}}

{{PMID Auto
|PMID=21531995
|Title=Clinical impact of scavenger receptor class B type I gene polymorphisms on human female fertility
}}
{{PMID|19041386|OA=1
}} Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: a systematic in-depth review.

{{PMID|19158204|OA=1
}} Scavenger receptor class B type I protein as an independent predictor of high-density lipoprotein cholesterol levels in subjects with hyperalphalipoproteinemia.

{{GET Evidence
|gene=SCARB1
|aa_change=Gly2Ser
|aa_change_short=G2S
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4238001
|overall_frequency_n=816
|overall_frequency_d=10032
|overall_frequency=0.0813397
|n_genomes=2
|n_genomes_annotated=0
|n_haplomes=1
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|pph2_score=0.937
|nblosum100=2
|autoscore=2
|webscore=N
|summary_short=Higher responsiveness to fenofibrate.
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}